Matching articles for "Wegovy"

Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Chronic Weight Management (online only)

   
The Medical Letter on Drugs and Therapeutics • August 5, 2024;  (Issue 1708)
...
View the Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Chronic Weight Management
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-2 | Show Full IntroductionHide Full Introduction

A New Indication for Semaglutide (Wegovy)

   
The Medical Letter on Drugs and Therapeutics • April 29, 2024;  (Issue 1701)
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) has been approved by the FDA to reduce the risk of major adverse cardiovascular events (MACE) in adults with established...
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) has been approved by the FDA to reduce the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease (CVD) and either obesity or overweight. Semaglutide is the first drug to be approved for cardiovascular risk reduction in this population. It is also approved in a lower-dose injectable formulation as Ozempic and in an oral formulation as Rybelsus (see Table 1).
Med Lett Drugs Ther. 2024 Apr 29;66(1701):66-7 | Show Full IntroductionHide Full Introduction

Tirzepatide (Zepbound) for Chronic Weight Management

   
The Medical Letter on Drugs and Therapeutics • December 25, 2023;  (Issue 1692)
The injectable glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide, which was approved by the FDA as Mounjaro for treatment of type 2 diabetes in...
The injectable glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide, which was approved by the FDA as Mounjaro for treatment of type 2 diabetes in 2022, has now been approved as Zepbound (Lilly) for chronic weight management in adults who have a BMI ≥30 kg/m2 or a BMI ≥27 kg/m2 and at least one weight-related comorbidity. The injectable GLP-1 receptor agonists liraglutide (Saxenda) and semaglutide (Wegovy) are approved for chronic weight management in patients ≥12 years old.
Med Lett Drugs Ther. 2023 Dec 25;65(1692):205-7 | Show Full IntroductionHide Full Introduction

In Brief: GI Effects of GLP-1 Receptor Agonists

   
The Medical Letter on Drugs and Therapeutics • November 27, 2023;  (Issue 1690)
Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro) are widely prescribed for treatment of type 2...
Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro) are widely prescribed for treatment of type 2 diabetes and weight management (see Table 1), but they delay gastric emptying and commonly cause nausea and vomiting. Gastroparesis and bowel obstruction (ileus) have also been reported with their use.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):191-2 | Show Full IntroductionHide Full Introduction

In Brief: Semaglutide (Wegovy) for Weight Loss in Children

   
The Medical Letter on Drugs and Therapeutics • February 20, 2023;  (Issue 1670)
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy), which was approved by the FDA in 2021 for chronic weight management in adults, has now been approved for chronic weight...
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy), which was approved by the FDA in 2021 for chronic weight management in adults, has now been approved for chronic weight management in children ≥12 years old with an initial BMI in the ≥95th percentile for age and sex.Semaglutide is also available as Ozempic and Rybelsus for treatment of type 2 diabetes in adults.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):31-2 | Show Full IntroductionHide Full Introduction

Drugs for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • November 14, 2022;  (Issue 1663)
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. Treating to a target A1C of...
Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes require antihyperglycemic drug therapy. Treating to a target A1C of <7% while minimizing hypoglycemia is recommended to prevent microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy). An A1C target of <8% may be appropriate for some older patients.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):177-84 | Show Full IntroductionHide Full Introduction

Tirzepatide (Mounjaro) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • July 11, 2022;  (Issue 1654)
The FDA has approved tirzepatide (Mounjaro – Lilly), a peptide hormone with activity at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, to improve...
The FDA has approved tirzepatide (Mounjaro – Lilly), a peptide hormone with activity at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, to improve glycemic control in adults with type 2 diabetes. Tirzepatide, which is injected subcutaneously once weekly, is the first dual GIP/GLP-1 receptor agonist to become available in the US. Selective GIP receptor agonists are not available in the US; GLP-1 receptor agonists have been available for years.
Med Lett Drugs Ther. 2022 Jul 11;64(1654):105-7 | Show Full IntroductionHide Full Introduction

Drugs and Devices for Weight Management

   
The Medical Letter on Drugs and Therapeutics • May 30, 2022;  (Issue 1651)
Adults with a body mass index (BMI) between 25 and 29.9 kg/m2 are considered overweight. Those with a BMI ≥30 are considered obese. The initial recommendation for any weight loss effort is to achieve a...
Adults with a body mass index (BMI) between 25 and 29.9 kg/m2 are considered overweight. Those with a BMI ≥30 are considered obese. The initial recommendation for any weight loss effort is to achieve a 5-10% reduction in weight, which has been associated with a reduction in the risk of developing type 2 diabetes, hypertension, and dyslipidemia. Diet, exercise, and behavior modification are the preferred methods for losing weight, but long-term weight maintenance can be difficult. Several drugs and devices are FDA-approved for weight reduction and maintenance of weight loss.
Med Lett Drugs Ther. 2022 May 30;64(1651):81-8 | Show Full IntroductionHide Full Introduction

Comparison Table: Some FDA-Approved Drugs for Weight Management (online only)

   
The Medical Letter on Drugs and Therapeutics • May 30, 2022;  (Issue 1651)
...
View the Comparison Table: Some FDA-Approved Drugs for Weight Management
Med Lett Drugs Ther. 2022 May 30;64(1651):e89-91 | Show Full IntroductionHide Full Introduction

In Brief: Higher-Dose Semaglutide (Ozempic) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • May 16, 2022;  (Issue 1650)
The FDA has approved a higher-dose injectable formulation of the long-acting glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Ozempic) for treatment of type 2 diabetes in adults. A single SC...
The FDA has approved a higher-dose injectable formulation of the long-acting glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Ozempic) for treatment of type 2 diabetes in adults. A single SC injection of the new 8 mg/3 mL formulation delivers 2 mg of semaglutide.
Med Lett Drugs Ther. 2022 May 16;64(1650):79 | Show Full IntroductionHide Full Introduction

Semaglutide (Wegovy) for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • July 12, 2021;  (Issue 1628)
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, previously approved by the FDA as Ozempic to treat type 2 diabetes and to reduce the risk of major adverse cardiovascular events...
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, previously approved by the FDA as Ozempic to treat type 2 diabetes and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, has now been approved in a higher dose as Wegovy (Novo Nordisk) for chronic weight management in adults with or without type 2 diabetes who have a body mass index (BMI) ≥30 kg/m2 or a BMI ≥27 kg/m2 and ≥1 weight-related comorbidity (e.g., hypertension, dyslipidemia). An oral formulation of semaglutide (Rybelsus) has been available since 2019 for treatment of type 2 diabetes, but it is not approved for weight management. Liraglutide (Saxenda), another subcutaneously injected GLP-1 receptor agonist, was approved for chronic weight management in 2015.
Med Lett Drugs Ther. 2021 Jul 12;63(1628):106-8 | Show Full IntroductionHide Full Introduction